Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHR708
MIFTS: 42

Chronic Urticaria

Categories: Immune diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Chronic Urticaria

About this section

MalaCards integrated aliases for Chronic Urticaria:

Name: Chronic Urticaria 12 15
Urticaria Chronic 54

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080747
Sources

Summaries for Chronic Urticaria

About this section
Disease Ontology : 12 An urticaria that is characterized by the presence of urticaria for a period exceeding 6 weeks, assuming symptoms for most days of the week.

MalaCards based summary : Chronic Urticaria, also known as urticaria chronic, is related to chronic inducible urticaria and chronic spontaneous urticaria. An important gene associated with Chronic Urticaria is HRH1 (Histamine Receptor H1), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and NF-kappaB Signaling. The drugs Omalizumab and Hydroxyzine have been mentioned in the context of this disorder. Affiliated tissues include skin, thyroid and endothelial, and related phenotype is immune system.

Sources

Related Diseases for Chronic Urticaria

About this section

Diseases in the Urticaria family:

Chronic Urticaria Rare Urticaria

Diseases related to Chronic Urticaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 473)
# Related Disease Score Top Affiliating Genes
1 chronic inducible urticaria 32.1 TPO FCER1A ENPP3
2 chronic spontaneous urticaria 31.6 PTGDR2 IL6 FCER1A CRP
3 angioedema 31.3 PTGS1 IGHE HRH1 HNMT CPN1 ACE
4 ige responsiveness, atopic 31.0 RNASE3 IL4 IL13 IGHE
5 cholinergic urticaria 31.0 HRH1 FCER1A ENPP3
6 physical urticaria 30.7 TPT1 HRH1 FCER1A ENPP3 CRP CD63
7 exanthem 30.6 IL6 CRP ACE
8 dermatitis 30.5 RNASE3 IL6 IL4 IL13 IGHE
9 food allergy 30.5 TPT1 RNASE3 IL4 IL13 IGHE HRH1
10 skin disease 30.5 RNASE3 IL6 IL4 IL13 HRH1 CRP
11 allergic rhinitis 30.5 TPT1 RNASE3 IL4 IL13 IGHE HRH1
12 strongyloidiasis 30.5 IL4 IL13 IGHE
13 penicillin allergy 30.5 IL4 IL13 IGHE
14 urticaria 30.5 TPT1 RNASE3 PTGS1 IL6 IL4 IL13
15 allergic disease 30.5 RNASE3 IL6 IL4 IL3 IL13
16 hereditary angioedema 30.4 CRP CPN1 ACE
17 thyroiditis 30.4 TPO TG IL6 IL4 CRP
18 hashimoto thyroiditis 30.4 TPO TG IL6 IL4
19 exercise-induced anaphylaxis 30.3 IGHE ENPP3
20 graves' disease 30.2 TPO TG IL4 IL13
21 thyroid gland disease 30.2 TPO TG IL6 CRP
22 allergic asthma 30.1 RNASE3 IL4 IL3 IL13 IGHE
23 milk allergy 30.1 RNASE3 IL4 IL13 IGHE
24 respiratory allergy 30.1 RNASE3 IL4 IL3 IL13 IGHE ENPP3
25 autoimmune disease 30.1 TPO TG IL6 IL4 IL13 CRP
26 syphilis 30.1 IGHE CRP ACE
27 hyperthyroidism 30.1 TPO TG IL6 CRP
28 alexithymia 30.1 IL6 IL4 CRP
29 toxocariasis 30.1 RNASE3 IL4 IL13 IGHE CRP
30 hypereosinophilic syndrome 30.1 RNASE3 IL4 IL3 IL13 IGHE
31 neurodermatitis 30.0 IL4 IL13
32 mastocytosis 30.0 IL6 IL4 IL3 IL13 ENPP3
33 rhinitis 30.0 TPT1 RNASE3 PTGS1 IL6 IL4 IL13
34 dermatographia 30.0 TPT1 IGHE FCER1A ENPP3 CD63
35 irritable bowel syndrome 30.0 IL6 IL4 CRP
36 celiac disease 1 30.0 TPO TG IL6 IL4 IL13 CRP
37 cryopyrin-associated periodic syndrome 29.9 IL6 CRP
38 latex allergy 29.9 RNASE3 IL4 IL13 IGHE
39 bullous pemphigoid 29.9 RNASE3 IL4 IL13 IGHE
40 dermatitis, atopic 29.9 RNASE3 PTGDR2 IL6 IL4 IL13 IGHE
41 toxic shock syndrome 29.9 IL6 IL4 CRP
42 angina pectoris 29.9 IL6 CRP ACE
43 alopecia areata 29.8 TPO IL6 IL4 IL13
44 filariasis 29.8 IL6 IGHE CRP
45 erythema nodosum 29.8 IL6 IL13 CRP
46 cystitis 29.8 IL6 IL4 CRP
47 sleep disorder 29.7 IL6 HRH1 CRP ACE
48 purpura 29.7 IL6 IL4 CRP ACE
49 meningitis 29.7 IL6 IL4 IL13 CRP
50 covid-19 29.7 IL6 IL4 ACE

Graphical network of the top 20 diseases related to Chronic Urticaria:



Diseases related to Chronic Urticaria
Sources

Symptoms & Phenotypes for Chronic Urticaria

About this section

MGI Mouse Phenotypes related to Chronic Urticaria:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.44 ACE CPN1 CRP ENPP3 FCER1A HRH1
Sources

Drugs & Therapeutics for Chronic Urticaria

About this section

Drugs for Chronic Urticaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4 242138-07-4
2
Hydroxyzine Approved Phase 4 68-88-2 3658
3
Cetirizine Approved Phase 4 83881-51-0 2678
4
Tranexamic Acid Approved Phase 4 1197-18-8 5526
5
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
6
Levocetirizine Approved Phase 4 130018-77-8 1549000
7
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
8 Respiratory System Agents Phase 4
9 Anti-Asthmatic Agents Phase 4
10 Immunoglobulins, Intravenous Phase 4
11 Immunoglobulin E Phase 4
12 Anti-Allergic Agents Phase 4
13 Hemostatics Phase 4
14 Coagulants Phase 4
15 Antifibrinolytic Agents Phase 4
16 Neurotransmitter Agents Phase 4
17 Histamine Antagonists Phase 4
18
Histamine Phosphate Phase 4 51-74-1 65513
19 Histamine H1 Antagonists Phase 4
20 Histamine H1 Antagonists, Non-Sedating Phase 4
21 Vitamins Phase 4
22 Calciferol Phase 4
23
Loratadine Approved, Investigational Phase 3 79794-75-5 3957
24
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
25
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
26
Desloratadine Approved, Investigational Phase 3 100643-71-8 124087
27
Cyproheptadine Approved Phase 3 129-03-3 2913
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
29 Immunosuppressive Agents Phase 3
30 Vitamin B Complex Phase 3
31 Folic Acid Antagonists Phase 3
32 Antimetabolites Phase 3
33 Vitamin B9 Phase 3
34 Folate Phase 3
35 Cholinergic Antagonists Phase 3
36 Dermatologic Agents Phase 3
37 Gastrointestinal Agents Phase 3
38
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
39
Clemastine Approved, Investigational Phase 2 15686-51-8 26987
40
Lactitol Approved, Investigational Phase 2 585-86-4 157355
41
Abatacept Approved Phase 1, Phase 2 332348-12-6 10237
42
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
43
Miltefosine Approved, Investigational Phase 2 58066-85-6 3600
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
46 Immunoglobulin G Phase 2
47 Immunologic Factors Phase 1, Phase 2
48 Antirheumatic Agents Phase 1, Phase 2
49 Antifungal Agents Phase 2
50 Antineoplastic Agents, Immunological Phase 1, Phase 2

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of 20 mg Levocetirizine and 15 mg Levocetirizine + 50 mg Bed-Time Hydroxyzine in Severe Chronic Urticaria in Adults: a Pilot, Randomized, Double-blind, Cross-over and Parallel, Active-controlled, Single-centre Study Completed NCT01250652 Phase 4 Levocetirizine;Levocetirizine plus Hydroxyzine
2 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria Completed NCT03111628 Phase 4 Omalizumab
3 Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria Completed NCT01701583 Phase 4 Omalizumab
4 Efficacy and Safety of Levocetirizine Alone or in Combination With Tranexamic Acid in the Treatment of Spontaneous Chronic Urticaria. Multicentric Controlled Randomized Study in Cross-over, Double-blind Recruiting NCT03789422 Phase 4 association of levocetirizine and tranexamic acid;Levocetirizine only
5 A Randomised Controlled Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria Enrolling by invitation NCT03991845 Phase 4 Vit D
6 Randomized Clinical Trial Evaluating the Efficacy of Methotrexate in Addition to Anti-H1 Versus Placebo and Anti-H1 in the Treatment of Severe Chronic Idiopathic Urticaria Completed NCT01960283 Phase 3 Methotrexate (Novatrex ®) + anti-H1;Placebo + anti-H1
7 Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Completed NCT01803763 Phase 2, Phase 3 Omalizumab (Xolair);Placebo
8 An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) Completed NCT00598611 Phase 3 desloratadine;desloratadine
9 Study of the Effects of Antipruritic Chinese Herbal Medicine on Chronic Urticaria: a Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial. Completed NCT01715740 Phase 3 Chinese Herbal Medicine (CHM);Placebo
10 Phase 3 Study, Exploratory, Disease Activity Controlled Dose Escalating Study to Assess the Efficacy, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Chronic Spontaneous Urticaria. Completed NCT02213367 Phase 3 Bilastine;Bilastine;Bilastin
11 A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin Completed NCT00619801 Phase 3 Levocetirizine;Placebo
12 A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria. Completed NCT01916967 Phase 3 Desloratadine;Placebo
13 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Symptoms of Allergic Rhinitis or Chronic Urticaria. Completed NCT00628108 Phase 3 Levocetirizine 1.25 mg
14 An Open-Label Study of the Effects of Desloratadine Treatment on the Quality of Life of Patients With Chronic Urticaria Completed NCT00795158 Phase 3 desloratadine
15 A Multi-center, Randomized, Double Blind, Dose Escalating Phase III Study on the Efficacy, Safety and Long Term Outcome of Continuous vs. on Demand Treatment of Chronic Spontaneous Urticaria With Rupatadine. Terminated NCT02358265 Phase 3 10 mg Rupatadine on demand;10 mg Rupatadine;20 mg Rupatadine;10 mg Rupatadine on demand (sham updosing to 20 mg)
16 A Randomized, 24 Weeks, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Adult Patients With Chronic Urticaria Who Exhibit IgE Against Thyroperoxidase Completed NCT00481676 Phase 2 Omalizumab 75-375 mg;Placebo to omalizumab;Loratadine;Clemastine
17 Randomized, Controlled, Blinded, Pilot Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients Completed NCT02643862 Phase 1, Phase 2 Xolair;Placebo
18 An Open-Label, Pilot Study to Assess the Efficacy and Safety of AK002 (Siglec-8) in Subjects With Antihistamine-Resistant Chronic Urticaria Completed NCT03436797 Phase 2 AK002
19 Multicenter, Double- Blinded, Placebo- Controlled, Randomized, Cross-over (2x2) Clinical Trial, to Assess Efficacy and Safety of a New Indication for Omalizumab (Xolair®, Novartis) in Autoimmune and no Autoimmune Chronic Urticaria. Completed NCT01713725 Phase 2
20 Effect of Anti-IgE in Chronic Urticaria Completed NCT00130234 Phase 2 Xolair® (Omalizumab)
21 A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children From 2 to <12 Years of Age With Allergic Rhinoconjunctivitis or Chronic Urticaria Completed NCT01081574 Phase 1, Phase 2 Bilastine
22 A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy. Completed NCT00886795 Phase 1, Phase 2 abatacept (Orencia ®)
23 Randomised, Double-blind, Placebo-controlled Study Terminated NCT01170949 Phase 2 Miltefosine;Placebo
24 Phase I/II Open Label Evaluation of the Safety and Efficacy of Rituximab in Patients With Chronic Urticaria (The Rituximab Urticaria Study - "RUSTY") Terminated NCT00216762 Phase 1, Phase 2 Rituximab
25 A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria Recruiting NCT03632291 Phase 1
26 A Two-part Exploratory Study Combining a Pilot Study in Healthy Subjects and Chronic Spontaneous Urticaria Patients (Part 1) and a Randomized, Subject, Investigator and Sponsor-blinded, Placebo Controlled, Study (Part 2) to Assess the MechAniSm of acTion of ligElizumab (QGE031) in Patients With Chronic uRticaria (MASTER) Recruiting NCT04513548 Phase 1 Ligelizumab;Placebo
27 Quality of Life,Anxity,Depression and Quality of Sleep in Patients With Chronic Urticaria Unknown status NCT03163875
28 T Cell Function in Chronic Idiopathic Urticaria Unknown status NCT01425593
29 Detection of Viral Particels in Urticaria Patients Unknown status NCT03151902
30 Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Completed NCT02285023
31 Monitoring Chronic Urticaria Basophil Irritability by Cytometry (Monocentric Study) Completed NCT02671006
32 Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test (UCT) Completed NCT02285049
33 The Natural History of Chronic Urticaria in Childhood: A Prospective Study Completed NCT01284426
34 Effect of Psychological Stress Intervention for Patients With Chronic Urticaria Completed NCT01111136
35 A Randomized Open Labeled Trial to Compare the Efficacy of Antihistamine Dosing-up and add-on Treatment With H2-receptor Antagonist in Patients With Chronic Urticaria Completed NCT03293225
36 A Prospective Non-interventional Study to Collect Real Life Clinical Data on the Impact of Therapy, the Diagnosis and Management of Chronic Urticaria in Patients Refractory to at Least One Course of H1 Antihistamine Therapy Completed NCT02626221
37 AWARE: A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation Completed NCT02435238
38 Development (and Validation) of an Instrument to Assess Disease Control in Patients With Urticaria (Urticaria Control Test) Completed NCT01614834
39 UCT - Development of an Instrument to Assess Disease Control in Patients With Chronic Urticaria (Urticaria Control Test) Completed NCT01610128
40 The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment Completed NCT01371877 Vitamin D3;Vitamin D3
41 Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria Completed NCT00385372
42 Association of Thyroid Autoimmunity and Chronic Urticaria in Taiwan Completed NCT00737451
43 Real-life Management and Therapeutic Outcome of Patients With Chronic Rhinitis and Chronic Urticaria in Thailand Completed NCT02000648
44 Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema Completed NCT00876369
45 Contact Allergens Causing Chronic Urticaria in a New England-Area Population Completed NCT00868036
46 Prospective, Observational, Longitudinal Cohort Study on the Role of Endothelial Cells in the Pathogenesis of Chronic Urticaria. Recruiting NCT03443362
47 Drug Survival of Omalizumab in Chronic Urticaria : a Retrospective Multicentric Study Recruiting NCT04584190
48 Real-life Study of How to Intensify Treatment With Xolair (OMALIZUMAB) in Chronic Spontaneous Urticaria Not yet recruiting NCT04583475
49 Effect of Psychological Stress Intervention on Chronic Urticaria Activity and Immune Dysregulation Withdrawn NCT01047137
50 Hydroxychloroquine Efficacy in Chronic Urticaria Withdrawn NCT01073852 Placebo;Hydroxychloroquine

Search NIH Clinical Center for Chronic Urticaria

Sources

Genetic Tests for Chronic Urticaria

About this section
Sources

Anatomical Context for Chronic Urticaria

About this section

MalaCards organs/tissues related to Chronic Urticaria:

40
Skin, Thyroid, Endothelial, Whole Blood, T Cells, Brain, Bone Marrow
Sources

Publications for Chronic Urticaria

About this section

Articles related to Chronic Urticaria:

(show top 50) (show all 2754)
# Title Authors PMID Year
1
Analgesics. 61 54
20519889 2010
2
[Influence of penetrative needling of Shendao (GV 11) on the symptom score and serum IgE content in chronic urticaria patients]. 54 61
19916293 2009
3
Simultaneous occurrence of chronic autoimmune urticaria and non-allergic asthma: a common mechanism? 61 54
19585861 2009
4
Association of specific IgE to staphylococcal superantigens with the phenotype of chronic urticaria. 54 61
18955792 2008
5
Urticaria and urticaria related skin condition/disease in children. 54 61
18700329 2008
6
Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus. 61 54
18341658 2008
7
Serum interleukin-18 in patients with chronic ordinary urticaria: association with disease activity. 54 61
17509061 2007
8
The effect of acupuncture on serum IgE level in patients with chronic urticaria. 61 54
17078446 2006
9
Significant correlation between the CD63 assay and the histamine release assay in chronic urticaria. 54 61
16792754 2006
10
Is there a role for antileukotrienes in urticaria? 61 54
16681569 2006
11
The thyroid and urticaria. 54 61
16131915 2005
12
Validation of basophil histamine release against the autologous serum skin test and outcome of serum-induced basophil histamine release studies in a large population of chronic urticaria patients. 54 61
16076300 2005
13
The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. 54 61
15784113 2005
14
[Chronic urticaria with alterations of the thyroid function and thyroid peroxidase antibodies]. 61 54
16042134 2005
15
Association between chronic urticaria and thyroid autoimmunity: a prospective study involving 99 patients. 61 54
15056996 2004
16
[Presence of anti-Helicobacter pylori, antithyroid, and high-affinity IgE receptor antibodies in patients with chronic urticaria]. 54 61
12940109 2003
17
[Chronic urticaria. Clinical evolution, autologous serum test, count and activation of basophils]. 61 54
12673955 2003
18
Chronic urticaria: a role for newer immunomodulatory drugs? 61 54
12688835 2003
19
Conditional autoantibodies in urticaria patients: a unifying hypothesis. 61 54
11764305 2001
20
Extraction of IgE-binding components of Helicobacter pylori by immunoblotting analysis in chronic urticaria patients. 54 61
11752878 2001
21
Epitope analysis and primary structures of variable regions of anti-human FcepsilonRI monoclonal antibodies, and expression of the chimeric antibodies fused with human constant regions. 61 54
11055388 2000
22
Treatment of chronic urticaria with thyroxine in an euthyroid patient with thyroglobulin and microsomal antibodies. 61 54
11056786 2000
23
Upregulation of CD40 and CD40 ligand expression in IgE-associated cutaneous diseases. 61 54
9394977 1997
24
Eosinophil cationic protein (ECP) level and its correlation with eosinophil number or IgE level of peripheral blood in patients with various skin diseases. 54 61
9279689 1997
25
Comparison of histamine-releasing factor recovered from skin and peripheral blood mononuclear cells of patients with chronic idiopathic urticaria. 61 54
8970437 1996
26
Polymorphism of IgE gene in chronic urticaria. 54 61
8934659 1996
27
Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. 54 61
8828024 1996
28
Blood eosinophils and serum eosinophil cationic protein in patients with acute and chronic urticaria. 54 61
18475708 1996
29
Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. 61 54
7683772 1993
30
Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. 54 61
1723343 1991
31
Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. 61 54
1685361 1991
32
Eosinophilic cationic protein (ECP) in skin disorders. 61 54
1685831 1991
33
[IgE levels and hypersensitivity to certain inhaled and food allergens in acute and chronic urticaria]. 61 54
2287742 1990
34
Rotational Thromboelastometry Profile in Children With Chronic Spontaneous Urticaria. 61
32282649 2021
35
Total IgE as a Marker for Chronic Spontaneous Urticaria. 61
33474856 2021
36
Chronic urticaria and common variable immunodeficiency (CVID): an association to remember. 61
33547100 2021
37
The global burden of chronic urticaria for the patient and society. 61
32956489 2021
38
Prevalence of Chronic Inducible Urticaria in Elderly Patients. 61
33445423 2021
39
Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice. 61
33475181 2021
40
Chronic urticaria with inflammation. 61
33208298 2021
41
Skin Prick Test Positivity in Chronic Urticaria. 61
33510498 2021
42
Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease. 61
32603278 2021
43
Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review. 61
33506984 2021
44
Chronic inducible urticaria subtypes in children: Clinical features and prognosis. 61
32741017 2021
45
Chronic urticaria in children under 15 years of age: Clinical experience beyond the clinical trials. 61
33410219 2021
46
Chronic Urticaria in Children - New Insights from a Large Cohort. 61
33502063 2021
47
Flame Figures in Linear Immunoglobulin A Bullous Dermatosis Secondary to Parvovirus B19 Infection. 61
32472771 2021
48
Peptic Ulcer Disease is Associated with Increased Risk of Chronic Urticaria Independent of Helicobacter pylori Infection: A Population-Based Cohort Study. 61
32915422 2021
49
Change in Allergy Practice during the COVID-19 Pandemic. 61
33059353 2021
50
New and emerging treatments for inflammatory itch. 61
32497711 2021
Sources

Variations for Chronic Urticaria

About this section
Sources

Expression for Chronic Urticaria

About this section
Search GEO for disease gene expression data for Chronic Urticaria.
Sources

Pathways for Chronic Urticaria

About this section

Pathways related to Chronic Urticaria according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.39 IL4 IL3 IL13 IGHE FCER1A
2
NF-kappaB Signaling 4
12.31 TPT1 PTGS1 IL4 IL3 ENPP3 CD63
3
JAK-STAT signaling pathway 36
Show member pathways
 12.27 IL6 IL4 IL3 IL13
4
Folate Metabolism 1
Show member pathways
 12.18 PTGS1 IL6 IL4 CRP
5
Allograft rejection 36 1
Show member pathways
 11.97 TPO TG RNASE3 IL6 IL4 IL3
6
Interleukin-4 and 13 signaling 65
11.76 IL6 IL4 IL13 IGHE
7
Glucocorticoid receptor regulatory network 1
11.66 IL6 IL4 IL13
8
Innate Lymphoid Cell Differentiation Pathways 64
11.64 PTGDR2 IL4 IL13
9
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.62 PTGDR2 IL6 IL4 IL3 FCER1A
10
Lung fibrosis 1
11.51 IL6 IL4 IL13
11
Interleukin-10 signaling 65
11.38 IL6 IL4 IL13
12
Hematopoietic Stem Cell Differentiation 1
11.35 TPO IL6 IL3
13
Differentiation Pathway 1
11.33 TPO IL6 IL3
14
Development and heterogeneity of the ILC family 1
11.11 IL6 IL4 IL13
15
Overview of nanoparticle effects 1
10.82 PTGS1 IL6 CRP
16
Cytokines and Inflammatory Response 1
10.72 IL6 IL4 IL3 IL13
17
IL-9 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types 64
10.51 IL6 IL4 IL13
18
Thyroxine (Thyroid Hormone) Production 1
10.3 TPO TG
Sources

GO Terms for Chronic Urticaria

About this section

Cellular components related to Chronic Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TG RNASE3 IL6 IL4 IL3 IL13
2 extracellular space GO:0005615 9.4 TPT1 TPO TG RNASE3 IL6 IL4

Biological processes related to Chronic Urticaria according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.77 PTGS1 IL6 IL13 HRH1 CRP
2 cytokine-mediated signaling pathway GO:0019221 9.65 IL6 IL4 IL3 IL13 IGHE
3 response to glucocorticoid GO:0051384 9.58 IL6 HNMT CPN1
4 macrophage activation GO:0042116 9.51 IL4 IL13
5 positive regulation of interleukin-10 production GO:0032733 9.5 IL6 IL4 IL13
6 hormone biosynthetic process GO:0042446 9.49 TPO TG
7 neutrophil mediated immunity GO:0002446 9.48 IL6 ACE
8 positive regulation of mast cell degranulation GO:0043306 9.46 IL4 IL13
9 negative regulation of lipid storage GO:0010888 9.43 IL6 CRP
10 immune response GO:0006955 9.43 PTGDR2 IL6 IL4 IL3 IL13 IGHE
11 negative regulation of complement-dependent cytotoxicity GO:1903660 9.16 IL4 IL13
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.92 IL6 IL4 IL3 IL13

Molecular functions related to Chronic Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IL6 IL4 IL3 IL13
Sources

Sources for Chronic Urticaria

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....